Lilly pumping up biotech efforts, spending millions in multi-mechanistic drugs pursuit
This article was originally published in Scrip
Executive Summary
In the midst of the largest international biotech convention, Lilly disclosed it plans to funnel millions of new dollars into its ongoing effort of developing biologics that have more than one mechanism of action – new engineered medicines described by one company official as "biobetters squared".